GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PT Merck Tbk (ISX:MERK) » Definitions » Cyclically Adjusted Revenue per Share

PT Merck Tbk (ISX:MERK) Cyclically Adjusted Revenue per Share : Rp2,216.86 (As of Mar. 2025)


View and export this data going back to 1981. Start your Free Trial

What is PT Merck Tbk Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

PT Merck Tbk's adjusted revenue per share for the three months ended in Mar. 2025 was Rp480.271. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is Rp2,216.86 for the trailing ten years ended in Mar. 2025.

During the past 12 months, PT Merck Tbk's average Cyclically Adjusted Revenue Growth Rate was -4.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 0.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -0.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of PT Merck Tbk was 0.70% per year. The lowest was -1.90% per year. And the median was -0.30% per year.

As of today (2025-05-23), PT Merck Tbk's current stock price is Rp3600.00. PT Merck Tbk's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was Rp2,216.86. PT Merck Tbk's Cyclically Adjusted PS Ratio of today is 1.62.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of PT Merck Tbk was 3.18. The lowest was 0.57. And the median was 1.68.


PT Merck Tbk Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for PT Merck Tbk's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PT Merck Tbk Cyclically Adjusted Revenue per Share Chart

PT Merck Tbk Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,251.53 2,226.43 2,290.28 2,300.49 2,241.07

PT Merck Tbk Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,311.92 2,261.89 2,225.64 2,241.07 2,216.86

Competitive Comparison of PT Merck Tbk's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, PT Merck Tbk's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PT Merck Tbk's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PT Merck Tbk's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where PT Merck Tbk's Cyclically Adjusted PS Ratio falls into.


;
;

PT Merck Tbk Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, PT Merck Tbk's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=480.271/131.9484*131.9484
=480.271

Current CPI (Mar. 2025) = 131.9484.

PT Merck Tbk Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 577.962 99.766 764.400
201509 501.438 101.037 654.851
201512 511.495 102.133 660.816
201603 682.950 102.764 876.905
201606 607.149 103.212 776.190
201609 511.985 104.142 648.685
201612 507.752 105.222 636.722
201703 706.096 106.476 875.017
201706 647.647 107.722 793.305
201709 651.338 108.020 795.618
201712 -705.969 109.017 -854.468
201803 315.565 110.097 378.198
201806 343.916 111.085 408.510
201809 369.190 111.135 438.334
201812 337.307 112.430 395.866
201903 364.200 112.829 425.917
201906 342.924 114.730 394.389
201909 404.435 114.905 464.425
201912 550.572 115.486 629.056
202003 362.158 116.252 411.056
202006 269.175 116.630 304.529
202009 350.410 116.397 397.228
202012 482.201 117.318 542.334
202103 565.536 117.840 633.246
202106 565.788 118.184 631.684
202109 623.329 118.262 695.468
202112 621.229 119.516 685.850
202203 673.139 120.948 734.361
202206 665.179 123.322 711.706
202209 601.944 125.298 633.891
202212 570.005 126.098 596.452
202303 582.881 126.953 605.819
202306 529.190 127.663 546.954
202309 630.230 128.151 648.903
202312 403.757 129.395 411.725
202403 556.911 130.607 562.631
202406 494.887 130.792 499.264
202409 630.652 130.361 638.332
202412 631.718 131.432 634.202
202503 480.271 131.948 480.271

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


PT Merck Tbk  (ISX:MERK) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

PT Merck Tbk's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3600.00/2216.86
=1.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of PT Merck Tbk was 3.18. The lowest was 0.57. And the median was 1.68.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


PT Merck Tbk Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of PT Merck Tbk's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


PT Merck Tbk Business Description

Industry
Traded in Other Exchanges
N/A
Address
Jalan T.B. Simatupang No. 8, Pasar Rebo, Jakarta Timur, IDN, 13760
PT Merck Tbk engages in the manufacture and sale of pharmaceutical products in Indonesia. The company operates in three segments: Biopharma, Consumer Health, and Others. The company offers pharmaceutical and biological prescription medicines for colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, as well as thyroid disorders such as hypothyroidism.

PT Merck Tbk Headlines

No Headlines